No events available.
Molecular Medicine
- Introduction to Division
- Key Personnel
- Projects
- Publications
- Activities & Events
- Careers
- Focus Areas
- Resources
Molecular Medicine
The Division of Molecular Medicine at St. John’s Research Institute (SJRI), Bengaluru, is dedicated to advancing translational research that bridges molecular insights with clinical outcomes. Its interdisciplinary focus spans cancer biology, hematology, renal genetics, and cell biology, with a strong emphasis on long‑term patient cohorts, mechanistic studies, and clinically relevant biomarkers. The division fosters collaboration across disciplines while nurturing the next generation of researchers.
Faculty Highlights:
- Dr. Jyothi S. Prabhu – Leads breast cancer research, establishing the breast cancer cohort and mapping molecular correlates of patient outcomes.
- Dr. Alok Srivastava – Pioneers hematology and stem cell biology, translating discoveries into therapies for blood disorders.
- Dr. Anil Vasudevan– Investigates renal genetics, focusing on inherited kidney diseases and their molecular basis.
- Dr. Neha Vyas – Explores how exovesicular Hedgehog release and miRNA packaging regulate Shh function in tissue patterning and cancer through tumor–stroma interactions.
- Dr. Madhumathy G Nair – Studies epigenetic regulation and tumor microenvironmental influences in cancer, emphasizing microRNAs, drug resistance, and oral carcinogenesis.
Key Personnel
Unit Head
Professor
I am a physician-scientist trained in clinical pathology and molecular medicine, with over twenty years of experience...
Lead
Senior Consultant /Department of Clinical Haematology & Bone Marrow Transplant
Dr. Alok SrivastavaSenior Consultant, Department of Clinical HaematologyHead, Haematology Research Unit, St. John’s ...
Associate Professor
21 years and I absolutely love what I do. My goal is to provide the highest level of care for children with kidney di...
Associate Professor
Patterning of developing embryos requires signaling via different molecules in spacio-temporally regulated manner. He...
Assistant Professor
Scientist with over 15 years of experience in oncology‑based translational research, and keen to explore the molecula...
Core Staff
Project staff in Haematology research group
Dr. Md. Manzoor Akheel is a seasoned professional with extensive experience in cell and gene therapy research operati...
Senior Lab Technician
I am actively involved in the histopathological processing and analysis of cancer tissues for research studies. My wo...
Senior Laboratory Technologist
As a Senior Lab Technologist, I am actively involved in performing molecular laboratory work and histopathological an...
NIH Fogarty INSIGHT fellow/ Research Scientist
I am a cancer biologist with interdisciplinary training in molecular biology, biophysics, and oncology, with a resear...
Research Associate
I am engaged in investigating the molecular mechanisms underlying aging through the identification and targeting of k...
Junior Research Fellow
Junior Research Fellow contributing to a DBT-funded study exploring dynamic epithelial-mesenchymal plasticity changes...
Project Technical Support III
Project Technical Support III under ICMR-PPBC project.
PhD Students
PhD scholar
Interested in understanding the role of nuclear receptors specifically the cross-talks of Estrogen, Progesterone, And...
PhD scholar
PhD Scholar affiliated to Manipal Academy of Higher Education (MAHE), working on a research project titled “Decipheri...
PhD scholar
PhD Scholar affiliated with Manipal Academy of Higher Education (MAHE) and currently working on a research project ti...
.webp)
Ph.D scholar
CSIR-UGC JRF- Ph.D StudentPh.D Scholar affiliated to Manipal Academy of Higher Education (MAHE), working on a researc...
Ph.D scholar
DST-INSPIRE FELLOW 2024Ph.D Scholar affiliated to Manipal Academy of Higher Education (MAHE), working on a research p...
PhD scholar
I am a bioinformatics consultant specializing in genome informatics and clinical and translational genomics, with a f...
| S.I. No | Title | Authors | Journal Name | Publication Year |
|---|---|---|---|---|
| 1 | Postpartum breast cancer as a distinct oncologic entity: linking physiological tissue remodelling to tumor biology and clinical translation | Vidya P. Nimbalkar, Snijesh V. P., Akash Dash, Meenakshi Jothikumar, Anjaney J. Pandey, P. S. Hari, Aruna Korlimarla, Sabarinathan Radhakrishanan & Jyothi S. Prabhu | Breast Cancer Research | 2026 |
| 2 | EPHA2-Ephrin-B1 cis-interaction drives an oncogenic reverse signaling, leading to the recurrence of oral cancer | Reshma Raj R, Nandini Datta, Soumya Krishnan U, Geetha Shanmugam, Jiss Maria Louis, Ravichandran Damodaran Jeyaram, Keshava K. Datta, Harsha Gowda, Meghna Sarkar, Madhumathy G. Nair, Jyothy S. Prabhu, Hafsa Shabeer, Balagopal P. G, Thameem A, Alan Jose, Vishnu Sunil Jaikumar & Tessy Thomas Maliekal | Cell Communication and Signaling | 2026 |
| 3 | Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response | Vidya P. Nimbalkar, V. P. Snijesh, Savitha Rajarajan, C. E. Anupama, S. Mahalakshmi, Annie Alexander, Deshica Dechamma, Manju Moorthy, Gopalakrishna Ramaswamy, Rakesh Ramesh, B. S. Srinath & Jyothi S. Prabhu | Journal of Translational Medicine | 2025 |
| 4 | Differential role of glucocorticoid receptor based on its cell type specific expression on tumor cells and infiltrating lymphocytes | Snijesh VP, Nimbalkar VP, Patil S, Rajarajan S, Anupama CE, Mahalakshmi S, Alexander A, Soundharya R, Ramesh R, Srinath BS, Jolly MK, Prabhu JS | Translational oncology | 2024 |
| 5 | Real time-PCR a diagnostic tool for reporting copy number variation and relative gene-expression changes in pediatric B-cell acute lymphoblastic leukemia-a pilot study | Zoha Sadaqat, Smitha Joseph, Chandrika Verma, Jyothi Muni Reddy, Anand Prakash, Tinku Thomas, Vandana Bharadwaj, Neha Vyas | Biology Methods and Protocol | 2024 |
| 6 | α-Fodrin-CENP-E interaction is critical for pancreatic cancer progression and drug response | Jyothy A, Hussain J, S SC, Chandraprabha VR, Nair MG, Vasudevan S, Sreedharan H, Abraham B, Maliekal TT, Natarajan K, Sengupta S. | Cell Cycle | 2024 |
| 7 | Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer | Sahoo S, Ramu S, Nair MG, Pillai M, San Juan BP, Milioli HZ, Mandal S, Naidu CM, Mavatkar AD, Subramaniam H, Neogi AG, Chaffer CL, Prabhu JS, Somarelli JA, Jolly MK. | iScience | 2024 |
| 8 | Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial-Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer | Nair MG, Mavatkar AD, Naidu CM, V P S, C E A, Rajarajan S, Sahoo S, Mohan G, Jaikumar VS, Ramesh RS, B S S, Jolly MK, Maliekal TT, Prabhu JS | Cells | 2024 |
| 9 | A comparative analysis of clinicopathological features and survival between pre and postmenopausal breast cancer from an Indian cohort. | Nimbalkar VP, Rajarajan S, V P S, Alexander A, Kaluve R, Selvam S, Ramesh R, B S S, Prabhu JS. | Sci Rep | 2023 |
| 10 | An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancers | Rajarajan S, Snijesh VP, Anupama CE, Nair MG, Mavatkar AD, Naidu CM, Patil S, Nimbalkar VP, Alexander A, Pillai M, Jolly MK, Sabarinathan R, Ramesh RS, Bs S, Prabhu JS | Translational Oncology | 2023 |
| 11 | PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer | Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP | Molecular Cancer | 2023 |
| 12 | The dynamic tumor-stromal crosstalk: implications of 'stromal-hot' tumors in the process of epithelial-mesenchymal transition in breast cancer | Mavatkar AD, Naidu CM, Prabhu JS, Nair MG | Molecular Biology Reports | 2023 |
| 13 | Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators | Richard V, Nair MG, Jaikumar VS, Jones S, Prabhu JS, Kerin MJ | International Journal of Molecular Sciences | 2023 |
| 14 | Estimation of ALU Repetitive Elements in Plasma as a Cost-Effective Liquid Biopsy Tool for Disease Prognosis in Breast Cancer | Nair MG, Ramesh RS, Naidu CM, Mavatkar AD, V P S, Ramamurthy V, Somashekaraiah VM, C E A, Raghunathan K, Panigrahi A, Das M, Dhar SK, Prabhu JS | Cancers | 2023 |
| 15 | Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers | Korlimarla A, Ps H, Prabhu J, Ragulan C, Patil Y, Vp S, Desai K, Mathews A, Appachu S, Diwakar RB, Bs S, Melcher A, Cheang M, Sadanandam A | Transl Oncol | 2022 |
| 16 | miR-18a Mediates Immune Evasion in ER-Positive Breast Cancer through Wnt Signaling | Nair MG, D A, M C, Vp S, Patil S, Ce A, Mukherjee G, Kumar RV, Prabhu JS, Ts S | Cells | 2022 |
| 17 | Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes | Rajarajan S, Korlimarla A, Alexander A, Anupama CE, Ramesh R, Srinath BS, Sridhar TS, Prabhu JS | Front Endocrinol (Lausanne) | 2021 |
| 18 | miRNAs: Critical mediators of breast cancer metastatic programming | Nair MG, Somashekaraiah VM, Ramamurthy V, Prabhu JS, Sridhar TS | Experimental Cell Research | 2021 |
| 19 | High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis | Nair MG, Prabhu JS, Ts S | Cancer Treatment and Research Communications | 2021 |
| 20 | miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis | Nair MG, Prabhu JS, Korlimarla A, Rajarajan S, P S H, Kaul R, Alexander A, Raghavan R, B S S, T S S | Cancer Medicine | 2020 |
| 21 | The Impact of Breast Cancer on the Patient and the Family in Indian Perspective | Alexander A, Kaluve R, Prabhu JS, Korlimarla A, Srinath BS, Manjunath S, Patil S, Gopinath KS, Sridhar TS. | Indian J Palliat Care | 2019 |
| 22 | HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells | Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A, Ce A, Alexander A, Kaluve RS, Manjunath S, Correa M, Srinath BS, Patil S, Kalamdani A, Prasad M, Sridhar TS | Tumour Biology | 2017 |
| 23 | Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease | Prabhu JS, Korlimarla A, Anupama CE, Alexander A, Raghavan R, Kaul R, Desai K, Rajarajan S, Manjunath S, Correa M, Raman R, Kalamdani A, Prasad M, Patil S, Gopinath KS, Srinath BS, Sridhar TS. | Transl Oncol | 2017 |
| 24 | Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer | Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS | PLoS One | 2016 |
| 25 | High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers | Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G, Kumar RV, Manjunath S, Correa M, Srinath BS, Patil S, Prasad MS, Gopinath KS, Rao RN, Violette SM, Weinreb PH, Sridhar TS | Cancer Medicine | 2016 |
| 26 | β3 integrin promotes chemoresistance to epirubicin in MDA-MB-231 through repression of the pro-apoptotic protein, BAD | Nair MG, Desai K, Prabhu JS, Hari PS, Remacle J, Sridhar TS | Experimental Cell Research | 2016 |
| 27 | Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypes | Nair MG, Desai K, Prabhu JS, Hari PS, Remacle J, Sridhar TS | Data Brief | 2016 |
| 28 | TM1-IR680 peptide for assessment of surgical margin and lymph node metastasis in murine orthotopic model of oral cancer | Suganya S AA, Kochurani KJ, Nair MG, Louis JM, Sankaran S, Rajagopal R, Kumar KS, Abraham P, P G B, Sebastian P, Somananthan T, Maliekal TT | Scientific Reports | 2016 |
| 29 | Live detection and purification of cells based on the expression of a histone chaperone, HIRA, using a binding peptide | Kochurani KJ, Suganya AA, Nair MG, Louis JM, Majumder A, Kumar SK, Abraham P, Dutta D, Maliekal TT | Scientific Reports | 2015 |
| 30 | Separate Quality-Control Measures Are Necessary for Estimation of RNA and Methylated DNA from Formalin-Fixed, Paraffin-Embedded Specimens by Quantitative PCR | Korlimarla A, Prabhu JS, Anupama CE, Remacle J, Wahi K, Sridhar TS | J Mol Diagn | 2014 |
| 31 | A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors | Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, Dendukuri N, Manjunath S, Correa M, Raman N, Kalamdani A, Prasad M, Gopinath KS, Srinath BS, Sridhar TS | J Cancer | 2014 |
| 32 | Identification of a non-canonical nuclear localization signal (NLS) in BRCA1 that could mediate nuclear localization of splice variants lacking the classical NLS | Korlimarla A, Bhandary L, Prabhu JS, Shankar H, Sankaranarayanan H, Kumar P, Remacle J, Natarajan D, Sridhar TS | Cell Mol Biol Lett | 2013 |
| 33 | Side population cells as prototype of chemoresistant, tumor-initiating cells | Richard V, Nair MG, Santhosh Kumar TR, Pillai MR | Biomed Research International | 2013 |
| 34 | Multiple drug resistant, tumorigenic stem-like cells in oral cancer | Richard V, Sebastian P, Nair MG, Nair SN, Malieckal TT, Santhosh Kumar TR, Pillai MR | Cancer Letter | 2013 |
| 35 | The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women | Prabhu JS, Wahi K, Korlimarla A, Correa M, Manjunath S, Raman N, Srinath BS, Sridhar TS | Tumour Biol | 2012 |
No book chapters available.
No books available.
No reports.
No other publications found.
No announcements available.
No news available.
No career openings at the moment.
No internships available.
No focus area details available.
No resources available.